CCL19 and neoplasm: Moreover, “armored” CARs, co-expressing cytokines such as IL-12, IL-15, or IL-7/Chemokine (C-C motif) ligand 19 (CCL19), have demonstrated superior proliferative capacity, metabolic fitness, persistence, and anti-tumor efficacy compared to conventional CARs devoid of cytokine support [117,118].